Acumen Pharmaceuticals, Inc.
ABOSHealthcare|Biotechnology|US
$0.22
+0.01 (+4.54%)
DCF Value
$0.38
Tangible Book / Share
$0.48
Cash / Share
$1.09
Financials
Financial Snapshot
Market Cap
$16.2M
Enterprise Value
-$10.6M
Revenue (TTM)
$0.00
Net Income (TTM)
-$104.0M
Cash & Investments
$78.6M
Net Cash
$52.3M
Free Cash Flow (TTM)
-$88.0M
Operating CF (TTM)
-$88.0M
Debt/Equity
0.76
Cash Runway & Burn Rate
Cash on Hand
$78.6M
Quarterly Burn
$22.0M
Monthly Burn
$7.3M
Est. Runway
~3.6 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $6.6M | $43.8M | $194.2M | $177.6M | $243.5M | $171.6M | $116.9M | $78.6M | |
| Operating Cash Flow | -$6.8M | -$7.5M | -$18.0M | -$35.2M | -$43.1M | -$86.2M | -$115.5M | -$88.0M | |
| Free Cash Flow | -$6.8M | -$7.5M | -$18.0M | -$35.3M | -$43.1M | -$86.2M | -$115.6M | -$88.0M | |
| Capital Expenditure | $0.00 | $0.00 | -$40.0K | -$161.0K | -$21.0K | -$16.0K | -$88.0K | $0.00 | |
| Financing Cash Flow | $6.2M | $44.7M | $200.5M | $3.9M | $151.8M | $6.9M | -$34.0K | $30.5M |
R&D Spending
R&D (TTM)
$85.9M
R&D Intensity
—
R&D Growth vs Prior
-18.1%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $1.4M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $8.6M | $8.0M | $12.3M | $32.4M | $42.3M | $93.8M | $104.9M | $85.9M | |
| R&D % of Revenue | 505.4% | 556.9% | — | — | — | — | — | — | |
| SG&A | $926.0K | $1.4M | $7.3M | $12.9M | $18.8M | $20.2M | $18.9M | $18.7M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $1.4M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $8.6M | $8.0M | $12.3M | $0.00 | $0.00 | $0.00 | $0.00 | $46.0K | |
| Gross Profit | -$6.9M | -$6.6M | -$12.3M | $0.00 | $0.00 | $0.00 | $0.00 | -$46.0K | |
| R&D | $8.6M | $8.0M | $12.3M | $32.4M | $42.3M | $93.8M | $104.9M | $85.9M | |
| SG&A | $926.0K | $1.4M | $7.3M | $12.9M | $18.8M | $20.2M | $18.9M | $18.7M | |
| Operating Income | -$7.8M | -$7.9M | -$19.6M | -$45.2M | -$61.1M | -$114.0M | -$123.8M | -$104.7M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $581.0K | $4.1M | $4.2M | $4.2M | |
| Pretax Income | -$7.9M | -$7.3M | -$100.6M | -$42.9M | -$52.4M | -$102.3M | -$121.3M | -$104.0M | |
| Net Income | -$7.9M | -$7.3M | -$100.6M | -$42.9M | -$52.4M | -$102.3M | -$121.3M | -$104.0M | |
| EPS (Diluted) | -0.27 | -0.26 | -2.63 | -1.06 | -1.08 | -1.71 | -2.00 | -1.55 | |
| EBITDA | $0.00 | -$7.9M | -$100.6M | -$42.7M | -$51.6M | -$98.1M | -$116.9M | -$99.6M | |
| Shares Out. (M) | 28.65 | 28.65 | 38.27 | 40.60 | 48.61 | 60.01 | 60.56 | 72.32 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.6M | $43.8M | $122.2M | $130.1M | $66.9M | $35.6M | $54.0M | $53.1M | |
| Short-Term Investments | $0.00 | $0.00 | $72.1M | $47.5M | $176.6M | $135.9M | $62.9M | $25.5M | |
| Total Current Assets | $7.2M | $44.4M | $198.7M | $180.3M | $246.6M | $178.3M | $122.3M | $85.1M | |
| Total Assets | $7.3M | $44.4M | $230.3M | $196.6M | $310.1M | $239.0M | $122.8M | $85.6M | |
| Total Current Liabilities | $1.3M | $6.4M | $5.1M | $7.8M | $13.0M | $27.6M | $30.0M | $45.1M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $27.3M | $29.4M | $22.4M | $5.9M | |
| Total Liabilities | $18.7M | $63.0M | $5.1M | $7.8M | $43.2M | $57.2M | $52.4M | $51.0M | |
| Stockholders' Equity | -$11.4M | -$18.6M | $225.2M | $188.8M | $267.0M | $181.8M | $70.4M | $34.6M | |
| Retained Earnings | -$19.6M | -$27.0M | -$127.6M | -$170.4M | -$222.8M | -$325.1M | -$446.5M | -$525.3M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.8M | -$7.5M | -$18.0M | -$35.2M | -$43.1M | -$86.2M | -$115.5M | -$88.0M | |
| Capital Expenditure | $0.00 | $0.00 | -$40.0K | -$161.0K | -$21.0K | -$16.0K | -$88.0K | $0.00 | |
| Free Cash Flow | -$6.8M | -$7.5M | -$18.0M | -$35.3M | -$43.1M | -$86.2M | -$115.6M | -$88.0M | |
| Investing Cash Flow | $0.00 | $0.00 | -$104.1M | $39.2M | -$171.7M | $48.0M | $133.9M | $63.7M | |
| Financing Cash Flow | $6.2M | $44.7M | $200.5M | $3.9M | $151.8M | $6.9M | -$34.0K | $30.5M | |
| Issuance of Stock | $0.00 | $0.00 | $168.6M | $3.8M | $121.9M | $7.9M | $39.0K | -$109.0K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$41.0K | -$73.0K | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $30.0M | -$739.0K | $0.00 | -$5.0M | |
| Stock Based Comp. | $174.0K | $154.0K | $922.0K | $3.1M | $6.1M | $9.6M | $9.9M | $10.0M | |
| Net Change in Cash | -$579.0K | $37.2M | $78.4M | $7.9M | -$63.0M | -$31.3M | $18.4M | $6.2M |
Dilution Tracker
Shares outstanding grew 111.4% over 5 years — significant dilution
Shares Outstanding
72M
5-Year Share Growth
+111.4%
Stock Issuance (TTM)
-$109.0K
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 28.65 | 28.65 | 38.27 | 40.60 | 48.61 | 60.01 | 60.56 | 72.32 | |
| Change vs Prior % | — | 0.0% | 33.6% | 6.1% | 19.7% | 23.5% | 0.9% | 19.4% | |
| Stock Issuance | $0.00 | $0.00 | $168.6M | $3.8M | $121.9M | $7.9M | $39.0K | -$109.0K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$41.0K | -$73.0K | $0.00 | |
| Stock Based Comp. | $174.0K | $154.0K | $922.0K | $3.1M | $6.1M | $9.6M | $9.9M | $10.0M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -405.4% | -456.9% | — | — | — | — | — | — | |
| Operating Margin % | -459.9% | -551.0% | — | — | — | — | — | — | |
| Net Margin % | -465.9% | -510.1% | — | — | — | — | — | — | |
| EBITDA Margin % | 0.0% | -551.0% | — | — | — | — | — | — | |
| FCF Margin % | -401.8% | -518.8% | — | — | — | — | — | — | |
| ROE % | 69.2% | 39.4% | -44.7% | -22.7% | -19.6% | -56.3% | -172.3% | -166.5% | |
| ROA % | -108.0% | -16.5% | -43.7% | -21.8% | -16.9% | -42.8% | -98.8% | -121.5% | |
| ROIC % | -130.5% | -20.8% | -8.7% | -24.0% | -20.5% | -53.9% | -121.7% | -172.0% | |
| R&D / Revenue % | 505.4% | 556.9% | — | — | — | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | -15.4% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 4.6% | -87.5% | 100.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -1.4% | -147.5% | -131.0% | -35.2% | -86.5% | -8.6% | |
| Net Income | 0.0% | 7.4% | -1273.5% | 57.4% | -22.2% | -95.4% | -18.6% | |
| EPS (Diluted) | 0.0% | 3.7% | -911.5% | 59.7% | -1.9% | -58.3% | -17.0% | |
| Operating Cash Flow | 0.0% | -9.3% | -141.1% | -95.7% | -22.5% | -100.2% | -34.0% | |
| Free Cash Flow | 0.0% | -9.3% | -141.6% | -96.2% | -22.0% | -100.1% | -34.1% | |
| R&D Expense | 0.0% | -6.8% | 53.9% | 163.0% | 30.8% | 121.7% | 11.8% | |
| SG&A Expense | 0.0% | 45.9% | 438.8% | 76.9% | 46.2% | 7.4% | -6.3% | |
| Total Assets | 0.0% | 506.8% | 418.4% | -14.6% | 57.8% | -22.9% | -48.6% | |
| Book Value / Share | 0.0% | -62.8% | 1006.9% | -21.0% | 18.4% | -45.0% | -61.6% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 27030.5% | 4.3% | 5.4% | |
| Diluted Shares | 0.0% | 0.0% | 33.6% | 6.1% | 19.7% | 23.5% | 0.9% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.47
10Y Low / Med / High0.57 / 1.15 / 1.81
EV/EBITDA0.11
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.38
Tangible Book / Share
$0.48
Net Current Assets / Share
$0.47
Graham Net-Net
$0.38
Cash / Share
$1.09
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -100.50 | -77.31 | -2.57 | -5.09 | -3.56 | -1.01 | -1.05 | -0.14 | |
| P/S Ratio | 339.36 | 401.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -50.43 | -30.98 | 1.15 | 1.16 | 0.70 | 0.57 | 1.81 | 0.47 | |
| EV/EBITDA | 0.00 | -67.26 | -1.36 | -2.09 | -2.86 | -0.99 | -0.90 | 0.11 | |
| EV/Revenue | 335.50 | 370.56 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-11.69
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $3.9M |
| Net Income | -$93.9M | -$42.2M | -$14.7M |
| EPS | $-1.51 | $-0.72 | $-0.24 |
| # Analysts (EPS) | 3 | 3 | 2 |